Diligent Investors LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 367 shares of the company's stock, valued at approximately $286,000.
Several other hedge funds have also recently added to or reduced their stakes in the company. WestEnd Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the 1st quarter worth $27,000. Citizens National Bank Trust Department lifted its stake in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the first quarter valued at about $40,000. Finally, TD Capital Management LLC grew its stake in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after buying an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company's stock.
Eli Lilly and Company Price Performance
Shares of Eli Lilly and Company stock opened at $840.46 on Friday. The business has a 50 day moving average of $734.60 and a 200 day moving average of $765.98. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a market cap of $795.47 billion, a PE ratio of 54.93, a P/E/G ratio of 1.17 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the firm earned $3.92 EPS. The company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Analyst Ratings Changes
LLY has been the subject of a number of recent research reports. JPMorgan Chase & Co. lowered their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, September 16th. Berenberg Bank reiterated a "hold" rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Morgan Stanley dropped their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research note on Friday. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Finally, Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $938.94.
Check Out Our Latest Research Report on LLY
Insider Activity at Eli Lilly and Company
In related news, CEO David A. Ricks purchased 1,632 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock valued at $2,894,841 over the last three months. Corporate insiders own 0.13% of the company's stock.
Eli Lilly and Company Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
